FiercePharma1h
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
Pensions&Investments7h
Ardian sees 2 senior dealmakers departing after 20 years
Two senior dealmakers are leaving Ardian after at least 20 years, people with knowledge of the matter said, marking the latest exits at the French private equity firm.
FiercePharma10h
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell
Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...